|
|
 |
|
Viewing report
|
|
|
|
Drug Repositioning: New Technologies, Business Models & Strategies for Successful Development
Arrowhead Publishers, Oct 2011, Pages: 155
Drug repositioning offers the possibility of breathing new life into pharmaceutical R&D. By recycling drug data, repositioning promises to boost production, accelerate and derisk R&D, and enhance product life-cycle management.
The promise of drug repositioning is now driving Big Pharma and Biotech to focus over 50% of its R&D activity into the approach. As the benefits of drug repositioning are being realized by industry; it is vital that stakeholders successfully navigate this challenging yet rewarding R&D paradigm.
This in-depth report delivers:
- Analysis of the scientific and technological strategies driving drug repositioning, successful business models, the role of Big Pharma and the financial reward of strategic drug repositioning
- Identification of the major challenges within strategic drug repositioning - examining the proof-of-concept clinical trial, regulatory hurdles, intellectual property barriers, selection of screening technologies and company organization
- Clinical and commercial analysis of classic and recently-approved repositioned products and key Phase III candidates
Report highlights:
With around 2,000 Phase II and Phase III failed pipeline candidates typically sitting idle in a typical pharma drug library, drug repositioning may resurrect abandoned R&D programs. Success will recoup R&D costs and provide novel, high-value product life-cycle management.
Arrowhead has identified over 50 specialist drug repositioning companies offering unique screening technologies. It is essential that players adopt a multi-disciplined approach by forming collaborations with specialists to gain valid, fast results to unveil new commercial opportunities.
This report will enable you to:
- Assess opportunities and risks influencing strategic drug repositioning R&D
- Identify key repositioned products in late-phase development based on sales forecasts to 2016, to maximize your product's commercial potential
- Gain an impartial perspective of strategies that can be used to enhance your product's performance in the drug repositioning arena
Key questions answered by this report:
- Why is there a need for drug repositioning in the biopharmaceutical industry?
- What are the major rewards offered by strategic drug repositioning?
- What are the major challenges involved in this paradigm; and how can they be overcome?
- Who are the key specialist players involved in the market and what business models are they utilizing?
- What lessons can investors learn from established repositioned brands?
- What products have recently gained FDA approval and what developmental pathway did they take?
- How can players optimize strategic drug repositioning to maximize commercial success?
- What are the key leading products and pipeline candidates in the market?
- How much revenue will the leading products and key pipeline agents reach by 2016?
- What financial rewards does the strategy provide?
- What recommendations does Arrowhead provide for successful repositioning?
- What does the future hold for the drug repositioning market?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
